Covid-19 vaccines and variants of concern: A review

Review Endocrinology & Metabolism

COVID-19 vaccine-induced myocarditis: Case report with literature review

Mahmoud Nassar et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

Add to Collection

Letter Cardiac & Cardiovascular Systems

MitraClip in Patients With and Without Cardiac Resynchronization Therapy

Agam Bansal et al.

AMERICAN JOURNAL OF CARDIOLOGY (2021)

Add to Collection

Article Allergy

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Milena Sokolowska et al.

Summary: The discussion focuses on the management and prevention of vaccine allergic reactions, providing a detailed algorithm for diagnosing and treating severe allergic reactions, along with recommendations for appropriate medications and equipment. A workup for identifying potential allergenic components in vaccines is proposed, along with a suggested international collaborative approach to reduce the risk of allergic reactions to COVID-19 vaccines.

ALLERGY (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Lindsey R. Baden et al.

Summary: The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing Covid-19 illness, including severe cases. Mild, transient local reactions were the only adverse effects, with low incidence of systemic reactions such as fever, headache, and fatigue.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: What new variants are emerging and how are they being investigated?

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021

et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Parasitology

One year update on the COVID-19 pandemic: Where are we now?

Sanjay Kumar Mishra et al.

Summary: The global COVID-19 pandemic has spurred scientific research to study the origin, structures, and pathogenesis of the virus, leading to the development of potential therapeutic and vaccine candidates. Despite the significant progress in understanding SARS-CoV-2 biology and therapeutics, treatment still relies heavily on supportive care. Researchers continue to work on developing effective strategies to combat the virus, with a focus on vaccine development and repurposing existing drugs.

ACTA TROPICA (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model

Sreelekshmy Mohandas et al.

Summary: The study demonstrated that the BBV152A and BBV152B vaccine candidates induced quick and robust immune responses, providing protection to Syrian hamsters from lung pathology after SARS-CoV-2 infection.

ISCIENCE (2021)

Add to Collection

Article Hematology

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede et al.

Summary: This study reports 5 cases of prothrombotic immune thrombocytopenia following vaccination with AZD1222. Patients presented with various clinical manifestations, including thrombocytopenia and elevated D-dimer levels. Treatment experience suggests that anticoagulation may be effective, but there is also a risk of unusual and severe thromboembolic events.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Dermatology

Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report

E. Akdas et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Letter Public, Environmental & Occupational Health

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Gajanan N. Sapkal et al.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff et al.

Summary: The Ad26.COV2.S vaccine, a replication-incompetent adenovirus vector, showed efficacy rates of 66% to 85% against Covid-19, and 64% to 82% against the South African variant. It demonstrated a good safety profile and was effective in protecting against severe-critical Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Reactive arthritis after COVID-19 vaccination

Qi-jun An et al.

Summary: Reactive arthritis (ReA) following COVID-19 vaccination is rare but the benefits of vaccination outweigh potential risks. Future attention should focus on identifying individuals at higher risk for developing autoimmune diseases after COVID-19 vaccination and exploring more versatile and safer vaccines.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Taufik Momin et al.

Summary: The Phase 1 trial of ZyCoV-D DNA vaccine conducted in India showed that the vaccine is safe, well-tolerated, and immunogenic, warranting further investigation.

ECLINICALMEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Current advances in the development of SARS-CoV-2 vaccines

Annoor Awadasseid et al.

Summary: COVID-19 caused by SARS-CoV-2 has become a global pandemic, with China being at the forefront of vaccine development. The last inactivated vaccine international clinical trial has been launched in the UAE, showing promising progress in creating efficacious and safe vaccines against SARS-CoV-2.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs

Godwell Nhamo et al.

Summary: The COVID-19 pandemic has exacerbated nationalism in vaccine and treatment procurement, threatening global solidarity. Wealthier countries have secured large quantities of vaccines and treatments in advance, posing significant challenges for low-income countries.

GLOBAL PUBLIC HEALTH (2021)

Add to Collection

Article Immunology

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study

Xiao-Ning Li et al.

Summary: The two-dose inactivated SARS-CoV-2 vaccine showed an effectiveness of 59.0% to 70.2% against the Delta variant, with higher efficacy among participants aged 40-59 years and in females compared to males in preventing COVID-19 and moderate diseases.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Biology

Origin, evolution and global spread of SARS-CoV-2

Anna Zhukova et al.

Summary: SARS-CoV-2 mainly evolves through point mutations, with the D614G mutation of the Spike protein affecting infectivity. As of September 30, 2020, no recombination of the virus has been documented in the human host. The global spread of the virus has been controversial, with new research proposing a solution to overcome previous limitations.

COMPTES RENDUS BIOLOGIES (2021)

Add to Collection

Article Biochemistry & Molecular Biology